OPG is regulated by β-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4713-4718

  De Toni, Enrico N ^a   Thieme, Susanne E ^b   Herbst, Andreas ^a   Behrens, Andrea ^a   Stieber, Petra ^c   Jung, Andreas ^d   Blum, Helmut ^b   Göke, Burkhard ^a   Kolligs, Frank T ^a,d  

^a Department of Medicine II ^*

^b Gene Center

^c University of Mu Nich   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; OSTEOPROTEGERIN; T CELL FACTOR 4 PROTEIN; T CELL FACTOR PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; WNT PROTEIN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; CANCER INVASION; COLON TUMOR; COLORECTAL TUMOR; DISEASE COURSE; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; METABOLISM; TUMOR CELL LINE;

APOPTOSIS; BETA CATENIN; CELL LINE, TUMOR; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; OSTEOPROTEGERIN; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 51049114701     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5019     Document Type: Article

References (22)

1. Eichhorst ST. Modulation of apoptosis as a target for liver disease. Expert Opin Ther Targets 2005;9:83-99.
2. Duiker EW, Mom CH, de Jong S, et al. The clinical trail of TRAIL. Eur J Cancer 2006;42:2233-40.
3. Herbst A, Kolligs FT Wnt signaling as a therapeutic target for cancer. Methods Mol Biol 2007;361:63-91.
4. Holen I, Shipman CM. Role of osteoprotegerin (OPG) in cancer. Clin Sci Lond 2006;110:279-91.
5. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991; 139:271-9.
6. Holen I, Croucher PI, Hamdy FC, Eaton CL Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002;62: 1619-23.
7. Theoleyre S, Wittrant Y, Tat SK, Fortun Y, Redini F, Heymann D. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev 2004; 15:457-75.
8. Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo-a role in tumour cell survival? Breast Cancer Res Treat 2005;92:207-15.
9. Pettersen I, Bakkelund W, Smedsrod B, Sveinbjornsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res 2005;25: 3809-16.
10. Glass DA, Bialek P, Ahn JD, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell 2005;8:751-64.
11. Pitti RM, Marsters SA, Ruppert S. Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996:271: 12687-90.
12. Takeda K, Smyth MJ, Cretney E, et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J Exp Med 2002:195:161-9.
13. Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updat 2004:7:345-58.
14. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005:12:228-37.
15. Eaton CL, Wells JM, Holen I, Croucher PI, Hamdy FC. Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. Prostate 2004:59:304-10.
16. Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res 2002:8:2306-10.
17. Clevers H. Wnt/|Vcatenin signaling in development and disease. Cell 2006:127:469-80.
18. llyas M. Wnt signalling and the mechanistic basis of tumour development. J Pathol 2005:205:130-44.
19. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov 2006:5 997-1014.
20. Bachmann MF, Wong BR, Josien R, Steinman RM, Oxenius A, Choi Y. TRANCE, a tumor necrosis factor family member critical for CD40 ligandindependent T helper cell activation. J Exp Med 1999, 189:1025-31.
21. Cretney E, Takeda K. Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosisinducing ligand-deficient mice. J Immunol 2002:168 1356-61.
22. Ito R, Nakayama H, Yoshida K, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch 2003:443:146-51.